Spearhead Capital Advisors LLC Has $1.20 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)
Spearhead Capital Advisors LLC Has $1.20 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)
Spearhead Capital Advisors LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 85.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,361 shares of the medical instruments supplier's stock after selling 32,521 shares during the quarter. Becton, Dickinson and makes up 1.3% of Spearhead Capital Advisors LLC's holdings, making the stock its 22nd biggest holding. Spearhead Capital Advisors LLC's holdings in Becton, Dickinson and were worth $1,195,000 as of its most recent SEC filing.
根据Speearhead Capital Advisors LLC向美国证券交易委员会(Securities&Exchange Commission)的最新披露,该公司在第三季度减持了Becton,Dickinson and Company(纽约证券交易所代码:BDX-GET评级)85.8%的股份。该机构投资者在本季度出售了32,521股后,持有这家医疗器械供应商的5,361股股票。Becton、Dickinson和占Spearhead Capital Advisors LLC所持股份的1.3%,使该股成为其第22大持股。截至最近提交给美国证券交易委员会的文件,先锋资本顾问公司持有的贝顿-迪金森公司股份价值1,19.5万美元。
Several other large investors have also bought and sold shares of BDX. Fairfield Bush & CO. bought a new position in Becton, Dickinson and in the first quarter valued at about $114,000. Sequoia Financial Advisors LLC raised its position in Becton, Dickinson and by 11.3% in the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier's stock valued at $778,000 after purchasing an additional 297 shares during the last quarter. Brighton Jones LLC raised its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier's stock valued at $368,000 after purchasing an additional 112 shares during the last quarter. Zions Bancorporation N.A. raised its position in Becton, Dickinson and by 13.0% in the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 58 shares during the last quarter. Finally, Mather Group LLC. raised its position in Becton, Dickinson and by 26.0% in the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier's stock valued at $358,000 after purchasing an additional 278 shares during the last quarter. 87.08% of the stock is owned by institutional investors and hedge funds.
其他几家大型投资者也买卖了BDX的股票。费尔菲尔德·布什公司在贝克顿、迪金森和第一季度购买了一个新头寸,估值约为11.4万美元。红杉金融顾问公司第一季度将其在Becton,Dickinson的持仓提高了11.3%。红杉金融顾问公司(Sequoia Financial Advisors LLC)在上个季度额外购买了297股后,现在拥有这家医疗器械供应商2923股股票,价值77.8万美元。Bright ton Jones LLC在第一季度将其在Becton,Dickinson的头寸提高了8.8%。Bright ton Jones LLC现在持有这家医疗器械供应商1,383股股票,价值36.8万美元,上个季度又购买了112股。Zion Bancorporation N.A.在第一季度将其在Becton,Dickinson的头寸提高了13.0%。Zion Bancorporation N.A.在上个季度额外购买了58股后,现在拥有这家医疗器械供应商504股股票,价值13.4万美元。最后,Mather Group LLC。第一季度将其在Becton,Dickinson的头寸提高了26.0%。Mather Group LLC.在上个季度又购买了278股后,现在拥有1346股这家医疗器械供应商的股票,价值35.8万美元。87.08%的股票由机构投资者和对冲基金持有。
Becton, Dickinson and Trading Down 1.1 %
Becton,Dickinson和Trading下跌1.1%
Shares of BDX stock opened at $245.84 on Friday. The company has a market cap of $69.88 billion, a P/E ratio of 46.38, a PEG ratio of 2.11 and a beta of 0.54. The stock has a 50 day simple moving average of $251.67 and a two-hundred day simple moving average of $244.53. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.63 and a current ratio of 1.07. Becton, Dickinson and Company has a fifty-two week low of $215.90 and a fifty-two week high of $280.62.
上周五,BDX的股票开盘报245.84美元。该公司市值为698.8亿美元,市盈率为46.38倍,聚乙二醇率为2.11倍,贝塔系数为0.54。该股的50日简单移动均线切入位为251.67美元,200日简单移动均线切入位为244.53美元。该公司的负债权益比率为0.56,速动比率为0.63,流动比率为1.07。Becton,Dickinson and Company的股价为52周低点215.90美元,52周高点为280.62美元。
Becton, Dickinson and Dividend Announcement
贝顿、狄金森和股息公告
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a yield of 1.48%. Becton, Dickinson and's dividend payout ratio (DPR) is presently 68.68%.
该公司最近还披露了季度股息,将于3月31日(星期五)支付。3月10日(星期五)登记在册的股东将获得0.91美元的股息。除息日期为3月9日(星期四)。这意味着年化股息为3.64美元,收益率为1.48%。Becton,Dickinson and的股息支付率(DPR)目前为68.68%。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities analysts have commented on BDX shares. Cowen dropped their target price on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. StockNews.com upgraded Becton, Dickinson and from a "hold" rating to a "buy" rating in a research report on Friday. The Goldman Sachs Group lowered their price objective on Becton, Dickinson and from $319.00 to $272.00 and set a "buy" rating for the company in a research report on Wednesday, November 23rd. Bank of America upgraded Becton, Dickinson and from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Finally, Evercore ISI lowered their price objective on Becton, Dickinson and to $270.00 in a research report on Wednesday, November 16th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and presently has an average rating of "Moderate Buy" and a consensus target price of $275.70.
几位股票分析师对BDX的股票发表了评论。Cowen在11月16日周三的一份研究报告中将他们对Becton和Dickinson的目标价下调至255.00美元。在周五的一份研究报告中,StockNews.com将Becton、Dickinson和的评级从持有上调至买入。11月23日周三,高盛夫妇在一份研究报告中将贝顿、狄金森的目标价从319.00美元下调至272.00美元,并为该公司设定了买入评级。1月3日周二,美国银行在一份研究报告中将Becton、Dickinson和的评级从中性上调至买入,并将其股票目标价从250.00美元上调至290.00美元。最后,Evercore ISI在11月16日星期三的一份研究报告中将他们对Becton,Dickinson的目标价格下调至270.00美元。两名分析师对该股的评级为持有,六名分析师对该公司的评级为买入。根据MarketBeat.com的数据,Becton、Dickinson和目前的平均评级为“中等买入”,共识目标价为275.70美元。
Becton, Dickinson and Profile
《贝顿、狄金森和肖像》
(Get Rating)
(获取评级)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
Becton,Dickinson&Co从事医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。它通过以下部门开展业务:BD医疗、BD生命科学和BD Intervative。BD医疗部门生产医疗技术和设备,用于帮助改善医疗保健服务。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免费获取StockNews.com关于Becton、Dickinson和(BDX)的研究报告
- 市场回顾周-1/30-2/3
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet盈利节节攀升,增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Get Rating).
想看看还有哪些对冲基金持有BDX吗?访问HoldingsChannel.com获取Becton,Dickinson and Company(纽约证券交易所代码:BDX-GET Rating)的最新13F文件和内幕交易。
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.
接受Becton Dickinson和Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Becton Dickinson和相关公司的最新新闻和分析师评级的每日简要摘要。